Extra Lymph Node Removal Surgery in High-Risk Kidney Cancer
Tests extra lymph node removal during kidney cancer surgery in adults with high-risk disease.
Plain-language title generated from the registry record
Registry title: Radical Nephrectomy With vs Without Template Lymph Node Dissection in High-Risk Renal Cell Carcinoma (T-LND RCC)
Key facts
- Where
- Tianjin, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with high-risk kidney cancer who will have their kidney removed. It compares removing many lymph nodes with removing only a few enlarged ones.
- Age
- Over 18 years
- Sex
- All sexes
- Disease stage
- High-risk renal cell carcinoma, for example cT3-4 N0-1 M0, a lymph node larger than 1cm (0.4 in), or a tumor of 10cm (3.9 in) or more together with other risk signs. The disease must be measurable (RECIST v1.1).
- Earlier treatment
- Cannot have had radiotherapy, chemotherapy, major surgery or targeted therapy for kidney cancer before.
Main reasons for not taking part
- Can have partial nephrectomy or ablation instead
- Lymph nodes that cannot be removed by surgery
- Another active cancer in the past 5 years
- Active or past autoimmune disease
- Known hereditary kidney cancer syndrome
Read by machine on 13 November 2026.
Where in China
- Tianjin Medical University Second HospitalTianjin, ChinaContact: Changyi QuanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Tianjin Medical University Second Hospital
- Trial code
- NCT07321197
- Record updated
- 25 June 2026
- Original description
The goal of this clinical trial is to learn if a more thorough lymph node removal surgery, called "Template Lymph Node Dissection," can help prevent cancer from returning and help patients live longer, compared to removing only a few enlarged lymph nodes, in patients with high-risk kidney cancer. The main questions it aims to answer are:Read full original descriptionShow less
Template Lymph Node Dissection for Tumor Control in High-Risk Renal Cell Carcinoma: A Prospective, Open-Label, Multicenter, Randomized Controlled Trial
The goal of this clinical trial is to learn if a more thorough lymph node removal surgery, called "Template Lymph Node Dissection," can help prevent cancer from returning and help patients live longer, compared to removing only a few enlarged lymph nodes, in patients with high-risk kidney cancer. The main questions it aims to answer are:
Do patients who receive template lymph node dissection live longer without their cancer returning (Disease-Free Survival)? Do patients who receive template lymph node dissection live longer overall (Overall Survival)? Is the more extensive lymph node surgery as safe as the limited surgery? Researchers will compare the Template Lymph Node Dissection group to the Limited Node Resection group to see the effects on cancer control and safety.
Participants will:
Be randomly assigned to one of the two surgical groups. Undergo surgery to remove their kidney and the assigned lymph nodes. Attend regular follow-up visits with imaging scans (like CT or MRI) for the first 5 years after surgery to monitor if the cancer returns.
Be followed for their overall survival status for up to 10 years.
Inclusion: Signed informed consent form; Age > 18 years; Candidate for radical nephrectomy with or without lymph node dissection; High-risk renal cell carcinoma defined as: At least ONE of: Clinical stage cT3-4 N0-1 M0 (AJCC 8th ed); OR radiologically visible lymph node >1cm; OR M1 disease rendered no evidence of disease (NED) after local therapy; OR radiologically determined rT4 stage. OR at least TWO of: Renal vein or inferior vena cava tumor thrombus; OR nuclear grade 3-4 or sarcomatoid differentiation or coagulative necrosis; OR tumor size >= 10cm; OR hematuria and/or local symptoms; Measurable disease as per RECIST v1.1; ECOG performance status of 0 or 1; Adequate bone marrow, renal, and hepatic function; For women and men of childbearing potential, agreement to use effective contraception during the study period.
Exclusion: Prior radiotherapy, chemotherapy, major surgery, or targeted therapy for RCC; Concurrent other active malignancy (except controlled malignancies not affecting 2-year survival); Use of immunosuppressive agents within 2 weeks prior to enrollment; Abdominal fistula, gastrointestinal perforation, or abscess within 4 weeks prior; renal tumors or known hereditary RCC syndrome; Diagnosis of any other active malignancy within the past 5 years; Active autoimmune disease or history of autoimmune disease; Poorly controlled cardiac or clinical symptoms; Coagulopathy or bleeding tendency; Active gastrointestinal conditions with risk of bleeding or perforation; History of significant bleeding or thromboembolic events within specified timeframes; Active infection or unexplained fever >38.5°C; History of pulmonary fibrosis, interstitial lung disease, or severely impaired pulmonary function; Known immunodeficiency or active hepatitis; Known history of drug abuse or alcohol addiction; Any condition that, in the investigator's judgment, may compromise patient safety or study conduct; Candidate for partial nephrectomy or ablation per multidisciplinary team assessment; Preoperative imaging indicates unresectable regional lymph nodes; Participation in another clinical trial within 1 month; Inability or unwillingness to bear the self-paid portion of examination and treatment costs.